{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:20:25Z","timestamp":1784172025096,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82422068"],"award-info":[{"award-number":["82422068"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2023KY622"],"award-info":[{"award-number":["2023KY622"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LR24H300001"],"award-info":[{"award-number":["LR24H300001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LDG25H300001"],"award-info":[{"award-number":["LDG25H300001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LHDMY23H310004"],"award-info":[{"award-number":["LHDMY23H310004"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejmech.2025.117745","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T18:40:17Z","timestamp":1746988817000},"page":"117745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Discovery of LC-SF-14, a selective dual inhibitor of SHP2 and FGFR for the treatment of FGFR2-driven gastric cancer"],"prefix":"10.1016","volume":"294","author":[{"given":"Lei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiansheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0089-6559","authenticated-orcid":false,"given":"Lingfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117745_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ctim.2016.02.014","article-title":"Synergistic effect of moxibustion and rehabilitation training in functional recovery of post-stroke spastic hemiplegia","volume":"26","author":"Wei","year":"2016","journal-title":"Compl. Ther. Med."},{"key":"10.1016\/j.ejmech.2025.117745_bib2","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.1038\/ncomms9859","article-title":"Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis","volume":"6","author":"Bunda","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117745_bib3","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.celrep.2018.07.006","article-title":"Noonan syndrome-associated SHP2 dephosphorylates GluN2B to regulate NMDA receptor function","volume":"24","author":"Levy","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.117745_bib4","doi-asserted-by":"crossref","first-page":"8816","DOI":"10.1158\/0008-5472.CAN-04-1923","article-title":"Activating mutations of the noonan syndrome-associated SHP2\/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia","volume":"64","author":"Bentires-Alj","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117745_bib5","doi-asserted-by":"crossref","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","article-title":"Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application","volume":"63","author":"Yuan","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.apsb.2020.07.010","article-title":"Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117745_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117745_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","article-title":"Crystal structure of the tyrosine phosphatase SHP-2","volume":"92","author":"Hof","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117745_bib9","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1021\/acs.jmedchem.1c02008","article-title":"Strategies targeting protein tyrosine phosphatase SHP2 for cancer therapy","volume":"65","author":"Song","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib10","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","article-title":"Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor","volume":"59","author":"Garcia Fortanet","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib11","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1080\/07391102.2020.1726817","volume":"39","author":"Wu","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2025.117745_bib12","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","article-title":"Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer","volume":"63","author":"LaMarche","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib13","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1021\/acsmedchemlett.5b00118","article-title":"Exploring the existing drug space for novel pTyr mimetic and SHP2 inhibitors","volume":"6","author":"He","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117745_bib14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117745_bib15","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","article-title":"RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers","volume":"20","author":"Nichols","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117745_bib16","doi-asserted-by":"crossref","first-page":"13534","DOI":"10.1021\/acs.jmedchem.4c00360","article-title":"Discovery of JAB-3312, a potent SHP2 allosteric inhibitor for cancer treatment","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112117","article-title":"Therapeutic potential of targeting SHP2 in human developmental disorders and cancers","volume":"190","author":"Shen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3005","article-title":"Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors","volume":"39","author":"Brana","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117745_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116579","article-title":"Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules","volume":"275","author":"Guo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.4497","article-title":"SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors","volume":"24","author":"Dardaei","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.117745_bib21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-20-2718","article-title":"Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling","volume":"27","author":"Liu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117745_bib22","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/2159-8290.CD-23-0361","article-title":"SHP2 inhibition sensitizes diverse oncogene-addicted solid tumors to Re-treatment with targeted therapy","volume":"13","author":"Drilon","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.117745_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117745_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","article-title":"FGF receptors: cancer biology and therapeutics","volume":"34","author":"Katoh","year":"2014","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.117745_bib25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.117745_bib26","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.tips.2016.10.003","article-title":"Therapeutics targeting FGF signaling network in human diseases","volume":"37","author":"Katoh","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.117745_bib27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13046-021-02156-6","article-title":"Fibroblast growth factor receptor fusions in cancer: opportunities and challenges","volume":"40","author":"Chen","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117745_bib28","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-21-1414","article-title":"Circulating tumor DNA analysis detects FGFR2 amplification and concurrent genomic alterations associated with FGFR inhibitor efficacy in advanced gastric cancer","volume":"27","author":"Jogo","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117745_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00428-013-1517-y","article-title":"FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation","volume":"464","author":"Betts","year":"2014","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ejmech.2025.117745_bib30","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.humpath.2015.06.007","article-title":"Fibroblast growth factor receptor 1 gene amplification in gastric adenocarcinoma","volume":"46","author":"Schafer","year":"2015","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ejmech.2025.117745_bib31","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1158\/1078-0432.CCR-16-0178","article-title":"An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients","volume":"22","author":"Piro","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117745_bib32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117745_bib33","doi-asserted-by":"crossref","first-page":"24252","DOI":"10.18632\/oncotarget.8132","article-title":"Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use","volume":"7","author":"Patani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.117745_bib34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.117745_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41571-020-0369-z","article-title":"Benefit from pemigatinib in cholangiocarcinoma","volume":"17","author":"Romero","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117745_bib36","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.117745_bib37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-Rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.117745_bib38","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/ijc.32665","article-title":"Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia\/lymphoma syndrome","volume":"146","author":"Chong","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117745_bib39","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1535-7163.MCT-18-0852","article-title":"SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors","volume":"18","author":"Lu","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117745_bib40","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by design: a medicinal chemist's perspective on multitargeting compounds","volume":"62","author":"Proschak","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib42","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.drudis.2011.10.003","article-title":"Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects","volume":"16","author":"L\u00f6tsch","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.117745_bib43","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.1021\/acs.jmedchem.2c00866","article-title":"Discovery of novel src Homology-2 domain-containing phosphatase 2 and histone deacetylase dual inhibitors with potent antitumor efficacy and enhanced antitumor immunity","volume":"65","author":"Liu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib44","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1021\/acs.jmedchem.2c00063","article-title":"Discovery of a novel src Homology-2 domain containing protein tyrosine Phosphatase-2 (SHP2) and cyclin-dependent kinase 4 (CDK4) dual inhibitor for the treatment of triple-negative breast cancer","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib45","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1021\/acs.jmedchem.0c00471","article-title":"Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib46","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1021\/acs.jmedchem.3c00150","article-title":"Discovery of a selective and orally bioavailable FGFR2 degrader for treating gastric cancer","volume":"66","author":"Ma","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115305","article-title":"Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-Driven cancer treatment","volume":"253","author":"Luo","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117745_bib48","doi-asserted-by":"crossref","first-page":"F351","DOI":"10.1152\/ajprenal.00232.2013","article-title":"Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4","volume":"306","author":"Gattineni","year":"2014","journal-title":"Am. J. Physiol-renal."},{"key":"10.1016\/j.ejmech.2025.117745_bib49","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.febslet.2012.05.008","article-title":"The human phosphatase interactome: an intricate family portrait","volume":"586","author":"Sacco","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2025.117745_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113963","article-title":"Dual target inhibitors based on EGFR: promising anticancer agents for the treatment of cancers (2017-)","volume":"227","author":"Hu","year":"2022","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:34:22Z","timestamp":1778535262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425005100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":50,"alternative-id":["S0223523425005100"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117745","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of LC-SF-14, a selective dual inhibitor of SHP2 and FGFR for the treatment of FGFR2-driven gastric cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117745","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117745"}}